FIBROBIOLOGICS INC
FBLGNASDAQTrading Snapshot
- Day Range
- $0.94 – $0.99
- 52-Week Range
- $0.62 – $9.60
- Volume (shares)
- 12,784.842
- Avg Volume (shares)
- —
- Shares Outstanding
- 7.0M
- Next Earnings
- 2026-10-30
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-5.74
- Dividend Yield
- —
- Dilution (1yr)
- +91.3%
FIBROBIOLOGICS INC
FBLG
StockOtter · stockotter.spaceAbout FIBROBIOLOGICS INC
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting
FSdC Spheroids Preserved Disc Height Better Than Any Other Fibroblast-Based Approach Tested in a 12-Week Rabbit Model of Degenerative Disc Disease HOUSTON, Oct. 19, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG
FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs
Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and Improve the Condition of Degenerated and Aged Discs HOUS
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body
New approach proposes an alternative to repeated injections HOUSTON, Oct. 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued an
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
Newly Granted Patent Covers Methods of Augmenting the Regenerative Efficacy of Fibroblasts Using Platelet Rich Plasma and Cytokines, with Claims Directed to Angiogenesis and Spinal Disc Regeneration HOUSTON, Sept. 29, 20
FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript
FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
HOUSTON, Sept. 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development